Karen Gelmon

Lipid/Polymer Nanoparticles as Tools to Improve the Therapeutic Activity of Existing and Emerging Anticancer Drug Combinations

Catherine Tucker, Euan Ramsay, Dawn Waterhouse, 2004, 2004 International Conference on MEMS, NANO and Smart Systems (ICMENS'04).

Breast Cancer Subtype Variation by Race and Ethnicity in a Diverse Population in British Columbia.

Diego Villa, Karen Gelmon, K. Gelmon, 2016, Clinical breast cancer.

Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes

Samuel Leung, David Huntsman, Dmitry Turbin, 2008, Breast Cancer Research.

Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.

John J Spinelli, Karen Gelmon, J. Spinelli, 2005, Journal of the National Cancer Institute.

Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.

Kristine R Broglio, Stephen Chia, Scott M Berry, 2016, JAMA oncology.

Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution

Sohrab P. Shah, Ali Bashashati, Hui Xue, 2014, Nature.

Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies

Päivi Heikkilä, Carlos Caldas, Simon S. Cross, 2010, PLoS medicine.

Metastatic behavior of breast cancer subtypes.

Karen Gelmon, T. Nielsen, M. Cheang, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers

Steven J. M. Jones, Stephen Yip, Marco A. Marra, 2015, Cold Spring Harbor molecular case studies.